Cargando…
Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects
AIMS: The safety and pharmacokinetics of single and multiple doses of a novel mGlu(2/3) receptor agonist prodrug, MGS0274 besylate (TS‐134), were investigated in healthy subjects. METHODS: Phase 1 single‐ascending dose (5–20 mg) and multiple‐ascending dose titration (5–80 mg) studies were conducted...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576618/ https://www.ncbi.nlm.nih.gov/pubmed/32353162 http://dx.doi.org/10.1111/bcp.14331 |
_version_ | 1783598050638299136 |
---|---|
author | Watanabe, Mai Marcy, Brian Kinoshita, Kohnosuke Fukasawa, Misako Hikichi, Hirohiko Chaki, Shigeyuki Okuyama, Shigeru Gevorkyan, Hakop Yoshida, Shigeru |
author_facet | Watanabe, Mai Marcy, Brian Kinoshita, Kohnosuke Fukasawa, Misako Hikichi, Hirohiko Chaki, Shigeyuki Okuyama, Shigeru Gevorkyan, Hakop Yoshida, Shigeru |
author_sort | Watanabe, Mai |
collection | PubMed |
description | AIMS: The safety and pharmacokinetics of single and multiple doses of a novel mGlu(2/3) receptor agonist prodrug, MGS0274 besylate (TS‐134), were investigated in healthy subjects. METHODS: Phase 1 single‐ascending dose (5–20 mg) and multiple‐ascending dose titration (5–80 mg) studies were conducted in healthy male and female subjects. Both studies were randomized, double‐blinded and placebo‐controlled. In one cohort of single‐ascending dose study (10 mg), concentrations of MGS0008, the active compound, in the cerebrospinal fluid (CSF) were measured for up to 24 hours postdose. RESULTS: Following single and multiple oral administrations, MGS0274 was rapidly absorbed and extensively converted into MGS0008, which reached a maximum concentration (C(max)) in plasma within 4 hours postdose and declined with a terminal half‐life (t(1/2)) of around 10 hours. Plasma exposure to MGS0274 was minimal, accounting for approximately 3% of the area under the concentration–time curve (AUC) of MGS0008. Plasma C(max) and AUC of MGS0008 at steady state increased dose proportionally (5–80 mg). MGS0008 penetrated into CSF, with a CSF‐to‐plasma C(max) ratio of 3.66%, and was eliminated with a t(1/2) of approximately 16 hours. The most frequent treatment‐emergent adverse events observed following single and multiple oral administration included headache, nausea, somnolence, dizziness and vomiting. CONCLUSION: TS‐134 is orally bioavailable in humans and converts rapidly and extensively to MGS0008, which exhibits good CSF penetration. Orally administered TS‐134 was safe and generally well‐tolerated; hence, TS‐134 is a promising candidate for further clinical development for the treatment of disorders in which glutamatergic abnormalities are involved, such as schizophrenia. |
format | Online Article Text |
id | pubmed-7576618 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75766182020-10-23 Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects Watanabe, Mai Marcy, Brian Kinoshita, Kohnosuke Fukasawa, Misako Hikichi, Hirohiko Chaki, Shigeyuki Okuyama, Shigeru Gevorkyan, Hakop Yoshida, Shigeru Br J Clin Pharmacol Original Articles AIMS: The safety and pharmacokinetics of single and multiple doses of a novel mGlu(2/3) receptor agonist prodrug, MGS0274 besylate (TS‐134), were investigated in healthy subjects. METHODS: Phase 1 single‐ascending dose (5–20 mg) and multiple‐ascending dose titration (5–80 mg) studies were conducted in healthy male and female subjects. Both studies were randomized, double‐blinded and placebo‐controlled. In one cohort of single‐ascending dose study (10 mg), concentrations of MGS0008, the active compound, in the cerebrospinal fluid (CSF) were measured for up to 24 hours postdose. RESULTS: Following single and multiple oral administrations, MGS0274 was rapidly absorbed and extensively converted into MGS0008, which reached a maximum concentration (C(max)) in plasma within 4 hours postdose and declined with a terminal half‐life (t(1/2)) of around 10 hours. Plasma exposure to MGS0274 was minimal, accounting for approximately 3% of the area under the concentration–time curve (AUC) of MGS0008. Plasma C(max) and AUC of MGS0008 at steady state increased dose proportionally (5–80 mg). MGS0008 penetrated into CSF, with a CSF‐to‐plasma C(max) ratio of 3.66%, and was eliminated with a t(1/2) of approximately 16 hours. The most frequent treatment‐emergent adverse events observed following single and multiple oral administration included headache, nausea, somnolence, dizziness and vomiting. CONCLUSION: TS‐134 is orally bioavailable in humans and converts rapidly and extensively to MGS0008, which exhibits good CSF penetration. Orally administered TS‐134 was safe and generally well‐tolerated; hence, TS‐134 is a promising candidate for further clinical development for the treatment of disorders in which glutamatergic abnormalities are involved, such as schizophrenia. John Wiley and Sons Inc. 2020-06-10 2020-11 /pmc/articles/PMC7576618/ /pubmed/32353162 http://dx.doi.org/10.1111/bcp.14331 Text en © 2020 Taisho Pharmaceutical R&D Inc. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Watanabe, Mai Marcy, Brian Kinoshita, Kohnosuke Fukasawa, Misako Hikichi, Hirohiko Chaki, Shigeyuki Okuyama, Shigeru Gevorkyan, Hakop Yoshida, Shigeru Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects |
title | Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects |
title_full | Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects |
title_fullStr | Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects |
title_full_unstemmed | Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects |
title_short | Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects |
title_sort | safety and pharmacokinetic profiles of mgs0274 besylate (ts‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576618/ https://www.ncbi.nlm.nih.gov/pubmed/32353162 http://dx.doi.org/10.1111/bcp.14331 |
work_keys_str_mv | AT watanabemai safetyandpharmacokineticprofilesofmgs0274besylatets134anovelmetabotropicglutamate23receptoragonistprodruginhealthysubjects AT marcybrian safetyandpharmacokineticprofilesofmgs0274besylatets134anovelmetabotropicglutamate23receptoragonistprodruginhealthysubjects AT kinoshitakohnosuke safetyandpharmacokineticprofilesofmgs0274besylatets134anovelmetabotropicglutamate23receptoragonistprodruginhealthysubjects AT fukasawamisako safetyandpharmacokineticprofilesofmgs0274besylatets134anovelmetabotropicglutamate23receptoragonistprodruginhealthysubjects AT hikichihirohiko safetyandpharmacokineticprofilesofmgs0274besylatets134anovelmetabotropicglutamate23receptoragonistprodruginhealthysubjects AT chakishigeyuki safetyandpharmacokineticprofilesofmgs0274besylatets134anovelmetabotropicglutamate23receptoragonistprodruginhealthysubjects AT okuyamashigeru safetyandpharmacokineticprofilesofmgs0274besylatets134anovelmetabotropicglutamate23receptoragonistprodruginhealthysubjects AT gevorkyanhakop safetyandpharmacokineticprofilesofmgs0274besylatets134anovelmetabotropicglutamate23receptoragonistprodruginhealthysubjects AT yoshidashigeru safetyandpharmacokineticprofilesofmgs0274besylatets134anovelmetabotropicglutamate23receptoragonistprodruginhealthysubjects |